De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
Eur Heart J
.
2012 Jul;33(13):1548-50.
doi: 10.1093/eurheartj/ehr408.
Epub 2011 Oct 31.
Authors
Benoit J Arsenault
,
S Matthijs Boekholdt
,
Jean-Claude Tardif
,
John J P Kastelein
PMID:
22041551
DOI:
10.1093/eurheartj/ehr408
No abstract available
Publication types
Editorial
Comment
MeSH terms
Animals
Anticholesteremic Agents / pharmacology*
Endothelium, Vascular / drug effects*
Hypertension / physiopathology*
Male
Quinolines / pharmacology*
Substances
Anticholesteremic Agents
Quinolines
torcetrapib